Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Everolimus (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Dec 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 12 Nov 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
- 06 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.